CD47 and neoplasm: Li et al., incorporated triptolide (TP) into tumor-targeting peptide RGD-modified liposomes and mixed it with tumor-derived exosomes expressing CD47, then performed vortex flow and sonication, vacuum vortexed for 15 min to remove the organic phase, and then hybrid nanoparticles containing TP were obtained by extrusion; miR497 was loaded into the above hybrid nanoparticles by subsequent experiments and used for the treatment of cisplatin-resistant ovarian cancer [71].